Evidence map›Paper›PMID 25621802›Full record

Trial reportBone marrow transplantation2015

Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.

K Patrick, W Lau, A Gassas, E McDougall, J Doyle, M Ali, J Krueger, S Courtney, C Armstrong, R M Egeler and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

K PatrickDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
W LauDepartment of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
A GassasDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
E McDougallDepartment of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
J DoyleDivision of Paediatric Haematology/Oncology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada.
M AliDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
J KruegerDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
S CourtneyDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
C ArmstrongDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
R M EgelerDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
T SchechterDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major ABO incompatible BM transplantation carries a risk of acute haemolysis. Red cell depletion reduces this risk but not all incompatible RBC (iRBCs) are removed and in children the residual volume can be significant relative to body weight. We sought to determine the volume of iRBCs that can be safely given to children. All patients receiving fresh BM from a donor with a major ABO blood group mismatch between January 2000 and July 2013 at the Hospital for Sick Children, Toronto, were included. Seventy-eight patients were identified. The median volume of iRBCs transfused was 1.6 mL/kg (range 0.1-10.6 mL/kg). Thirty-five patients had minor haemolytic events and five patients had clinically significant adverse events. Two patients, who received 3.66 and 3.9 mL iRBCs/kg, developed renal impairment and in one case hypoxia and hyperbilirubinaemia. One patient had mild hypotension that resolved with i.v. fluid. Two patients developed hypotension secondary to sepsis and unrelated to BM infusion. Although signs of haemolysis occur, with appropriate hydration and monitoring of renal function, clinically significant adverse events related to the infusion of ABO incompatible BM are rare, and, in this study, were only seen in patients receiving >3 mL/kg of iRBCs per kg.

Indexed as

ABO Blood-Group SystemBone Marrow TransplantationErythrocytesErythrocyte TransfusionTissue DonorsAdolescentChildChild, PreschoolFemaleHemolysisHumansInfantMaleABO Blood-Group System

Identifiers

PMID25621802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.